1. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 2007. Publication No. 07-4051.

2. Ramsdell JW, Fish L, Graft D, et al. A controlled trial of twice daily triamcinolone oral inhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol. 1998;80(5):385-390.

3. Data on file, Abbott Laboratories.

4. Bernstein DI, Cohen R, Ginchansky E, et al. Clinical aspects of allergic disease: a multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 mcg per day) for the treatment of patients with mild-to-moderate asthma. J Allergy Clin Immunol. 1998;101(4):433-438.

5. AZMACORT (triamcinolone acetonide) Inhalation Aerosol, Prescribing Information, Abbott Laboratories.

6. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007. Available from: http://www.ginasthma.org. Accessed May 30, 2008.

7. Pedersen S. Spacer Devices: Global Initiative for Asthma (GINA) Science Committee 2003. Available from http://www.ginasthma.org. Accessed May 30, 2008.

8. National Asthma Education and Prevention Program. Practical Guide for the Diagnosis and Management of Asthma. 1997. Bethesda, MD; National Institutes of Health. Publication No. 97-4053.